Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 10, Issue 9, 2008, Pages 739-746

  Brooks, Belinda A ^a,b   Franjic, B ^a   Ban, C R ^b   Swaraj, K ^a   Yue, D K ^a,b   Celermajer, D S ^a,b   Twigg, S M ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Diastolic dysfunction; Endothelium; Microvascular blood flow

Indexed keywords

ACETYLCHOLINE; CONNECTIVE TISSUE GROWTH FACTOR; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE; HEART VENTRICLE FILLING; HUMAN; IMMUNOBLOTTING; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PROTEIN EXPRESSION; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

EID: 50249098706     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00803.x     Document Type: Article

References (43)

1. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
2. Liu JE, Palmieri V, Roman MJ et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: The Strong Heart Study. J Am Coll Cardiol 2001; 37: 1943-1949.
3. Celentano A, Vaccaro O, Tammaro P et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol 1995; 76: 1173-1176.
4. Boyer JK, Thanigaraj S, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004; 93: 870-875.
5. Devereux RB, Roman MJ, Paranicas M et al. Impact of diabetes on cardiac structure and function: The strong heart study. Circulation 2000; 101: 2271-2276.
6. Di Bonito P, Cuomo S, Moio N et al. Diastolic dysfunction in patients with non-insulin-dependent diabetes mellitus of short duration. Diabet Med 1996; 13: 321-324.
7. Fang ZY, Schull-Meade R, Downey M, Prins J, Marwick TH. Determinants of subclinical diabetic heart disease. Diabetologia 2005; 48: 394-402.
8. Nicolino A, Longobardi G, Furgi G et al. Left ventricular diastolic filling in diabetes mellitus with and without hypertension. Am J Hypertens 1995; 8: 382-389.
9. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001; 24: 5-10.
10. Saraiva RM, Duarte DM, Duarte MPC et al. Tissue Doppler imaging identifies asymptomatic normotensive diabetics with diastolic dysfunction and reduced exercise tolerance. Echocardiography 2005; 22: 561-570.
11. Suys BE, Katier N, Rooman RP et al. Female children and adolescents with type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyopathy. Diabetes Care 2004; 27: 1947-1953.
12. Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001; 87: 320-323.
13. Cosson S, Kevorkian JP, Virally ML et al. No evidence of left ventricular diastolic dysfunction in asymptomatic normotensive type 2 diabetic patients: A case-control study with new echocardiographic techniques. Diabetes Metab 2007; 33: 61-67.
14. Mathew P, John L, Jose J, Krishnaswami S. Assessment of left ventricular diastolic function in young diabetics - a two dimensional echo Doppler study. Indian Heart J 1992; 44: 29-32.
15. Posner J, Ilya R, Wanderman K, Weitzman S. Systolic time intervals in diabetes. Diabetologia 1983; 24: 249-252.
16. Salazar J, Rivas A, Rodriguez M, Felipe J, Garcia MD, Bone J. Left ventricular function determined by Doppler echocardiography in adolescents with type I (insulin-dependent) diabetes mellitus. Acta Cardiol 1994; 49: 435-439.
17. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
18. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269.
19. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-1574.
20. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948-1955.
21. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 1993; 42: 1017-1025.
22. Treasure CB, Vita JA, Cox DA et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990; 81: 772-779.
23. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993; 22 (Suppl. 4): S1-S14.
24. Playford D, Watts GF. Endothelial dysfunction, insulin resistance and diabetes: Exploring the web of causality. Aust N Z J Med 1999; 29: 523-534.
25. Cooke JP, Tsao PS. Is NO an endogenous antiatherogenic molecule?. Arterioscler Thromb 1994; 14: 653-655 (Comment).
26. Candido R, Forbes JM, Thomas MC et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-792 (Comment).
27. Way KJ, Isshiki K, Suzuma K et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002; 51: 2709-2718.
28. Andersen S, van Nieuwenhoven FA, Tarnow L et al. Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney Int 2005; 67: 2325-2329.
29. Roestenberg P, van Nieuwenhoven FA, Wieten L et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004; 27: 1164-1170.
30. Keil A, Blom IE, Goldschmeding R, Rupprecht HD. Nitric oxide down-regulates connective tissue growth factor in rat mesangial cells. Kidney Int 2002; 62: 401-411.
31. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25: 543-567.
32. Rendell M, Bergman T, O'Donnell G, Drobny E, Borgos J, Bonner RF. Microvascular blood flow, volume, and velocity measured by laser Doppler techniques in IDDM. Diabetes 1989; 38: 819-824.
33. Veves A, Akbari CM, Primavera J et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998; 47: 457-463.
34. Westerman RA, Widdop RE, Hannaford J et al. Laser Doppler velocimetry in the measurement of neurovascular function. Australas Phys Eng Sci Med 1988; 11: 53-66.
35. Lubien E, DeMaria A, Krishnaswamy P et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601 (Comment) (Erratum in Circulation 2002; 106: 387).
36. Riser BL, Denichilo M, Cortes P et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11: 25-38.
37. Tikellis C, Cooper ME, Twigg SM, Burns WC, Tolcos M. Connective tissue growth factor is up-regulated in the diabetic retina: Amelioration by angiotensin-converting enzyme inhibition. Endocrinology 2004; 145: 860-866.
38. Ryden L, Armstrong PW, Cleland JG et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000; 21: 1967-1978.
39. Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77: 1017-1020.
40. Croft JB, Giles WH, Pollard RA, Casper ML, Anda RF, Livengood JR. National trends in the initial hospitalization for heart failure. J Am Geriatr Soc 1997; 45: 270-275.
41. Polanczyk CA, Rohde LE, Dec GW, DiSalvo T. Ten-year trends in hospital care for congestive heart failure: Improved outcomes and increased use of resources. Arch Intern Med 2000; 160: 325-332.
42. Arai M, Koitabashi N, Niwano K et al. The role of CCN2/CTGF in the development of cardiac fibrosis and its clinical utility for the diagnosis of heart failure. Fourth International Workshop on the CCN Family of Genes. J Cell Commun Signal 2007; 1: 77-78.
43. Nguyen TQ, Tarnow L, Andersen S et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006; 29: 83-88.